A decoy mutant ACE2 designed to reduce COVID-19. (September 2022)

• Record Type: Journal Article
• Authors: Maishan, Mazharul; Lim, Diana L.; Zimmerman, Guy A.; Matthay, Michael A.
• Is Part Of: Trends in pharmacological sciences. Volume 43:Number 9(2022)
• Page Start: 703
• Page End: 705
• Publication Date: 2022-09
• Subjects: ARDS -- viral pneumonia -- COVID-19 therapy; Pharmacology -- Periodicals; Pharmacology -- trends -- Periodicals; Pharmacologie -- Périodiques; Pharmacology; Electronic journals; Periodicals; 615.1
• DOI: 10.1016/j.tips.2022.02.010
• Languages: English
• ISSNs: 0165-6147

Abstract

Abstract : The need for new coronavirus disease 2019 (COVID-19) therapeutic strategies continues, especially as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge. Zhang and colleagues elegantly engineered a mutant angiotensin-converting enzyme 2 (ACE2) that competitively binds SARS-CoV-2 spike protein, reduces viral uptake by human lung cells, and ameliorates SARS-CoV-2-induced lung injury in mice expressing human ACE2.